CO6410307A2 - Formulación de doramectina en dosis elevada - Google Patents

Formulación de doramectina en dosis elevada

Info

Publication number
CO6410307A2
CO6410307A2 CO11111108A CO11111108A CO6410307A2 CO 6410307 A2 CO6410307 A2 CO 6410307A2 CO 11111108 A CO11111108 A CO 11111108A CO 11111108 A CO11111108 A CO 11111108A CO 6410307 A2 CO6410307 A2 CO 6410307A2
Authority
CO
Colombia
Prior art keywords
high dose
doramectine
formulation
doramectin
antiparasitic
Prior art date
Application number
CO11111108A
Other languages
English (en)
Inventor
Alvimar Jose Costa
Stephen Lee Secreast
Rodrigo Valarreli
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO6410307A2 publication Critical patent/CO6410307A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Abstract

Se describen composiciones veterinarias que proporcionan una dosis elevada de doramectina o una composición politerápica veterinaria en dosis elevada que comprende doramectina y un antiparasitario o más. Las composiciones dan a conocer una eficacia antiparasitaria y un tiempo de retención significativamente reducido.
CO11111108A 2009-02-16 2011-08-30 Formulación de doramectina en dosis elevada CO6410307A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15291109P 2009-02-16 2009-02-16
US21983709P 2009-06-24 2009-06-24

Publications (1)

Publication Number Publication Date
CO6410307A2 true CO6410307A2 (es) 2012-03-30

Family

ID=42060687

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11111108A CO6410307A2 (es) 2009-02-16 2011-08-30 Formulación de doramectina en dosis elevada

Country Status (20)

Country Link
US (1) US8551962B2 (es)
EP (1) EP2396006B1 (es)
JP (1) JP2012517994A (es)
KR (1) KR101326428B1 (es)
CN (1) CN102316876B (es)
AR (1) AR075428A1 (es)
AU (1) AU2010233409B2 (es)
BR (1) BRPI1008822B1 (es)
CA (1) CA2750626C (es)
CL (1) CL2011001775A1 (es)
CO (1) CO6410307A2 (es)
DK (1) DK2396006T3 (es)
ES (1) ES2399228T3 (es)
HK (1) HK1161087A1 (es)
MX (1) MX2011008614A (es)
NZ (1) NZ594389A (es)
PL (1) PL2396006T3 (es)
PT (1) PT2396006E (es)
WO (1) WO2010116267A1 (es)
ZA (1) ZA201105310B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2825154A4 (en) * 2012-03-13 2015-11-11 Bayer New Zealand Ltd LONG ACTIVE COMPOSITIONS
ES2436249B1 (es) * 2012-06-25 2014-06-23 Javier Alberto ALONSO-VAQUERO VELASCO Composición antiparasitaria para el control y tratamiento de parásitos de diferentes especies animales, caracterizada por combinar Moxidectina con las vitaminas: A, D3, y E
WO2014098623A1 (en) * 2012-12-20 2014-06-26 Alleva Animal Health Limited Injectable eprinomectin formulation and anthelmintic use thereof
CN103977017B (zh) * 2014-06-03 2016-09-07 重庆布尔动物药业有限公司 一种兽用抗寄生虫注射液及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8800986A1 (es) 1985-07-27 1987-12-01 Pfizer Un procedimiento para la produccion de un nuevo derivado de avermectina
ES2052173T3 (es) * 1989-04-11 1994-07-01 Pfizer Composiciones inyectables que contienen 25-cyclohexil-avermectina b1.
US6001822A (en) 1989-04-11 1999-12-14 Pfizer Inc. Antiparasitic formulations
CA2233016C (en) 1995-09-25 2007-07-17 Ashmont Holdings Limited Anthelmintic macrocyclic lactone compositions
DE19613972A1 (de) 1996-04-09 1997-10-16 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
US6214367B1 (en) 1996-06-05 2001-04-10 Ashmont Holdings Limited Injectable compositions
DE19638045A1 (de) * 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
US6174540B1 (en) 1998-09-14 2001-01-16 Merck & Co., Inc. Long acting injectable formulations containing hydrogenated caster oil
KR20000025762A (ko) * 1998-10-14 2000-05-06 유충식 이버멕틴류의 가용화 조성물
GB9825402D0 (en) * 1998-11-19 1999-01-13 Pfizer Ltd Antiparasitic formulations
GB9827727D0 (en) 1998-12-16 1999-02-10 Pfizer Ltd Antiparasitic formulations
CN1304727A (zh) * 2000-10-20 2001-07-25 王玉万 一种以苯甲酸苄酯或氮酮为助溶剂的含阿维菌素或伊维菌素的注射液

Also Published As

Publication number Publication date
BRPI1008822A2 (pt) 2016-03-08
CA2750626A1 (en) 2010-10-14
US20110294751A1 (en) 2011-12-01
AR075428A1 (es) 2011-03-30
PL2396006T3 (pl) 2013-06-28
PT2396006E (pt) 2013-02-13
KR101326428B1 (ko) 2013-11-20
CN102316876A (zh) 2012-01-11
BRPI1008822B1 (pt) 2019-04-09
AU2010233409B2 (en) 2012-05-17
ES2399228T3 (es) 2013-03-26
KR20110116231A (ko) 2011-10-25
NZ594389A (en) 2012-09-28
DK2396006T3 (da) 2013-02-11
WO2010116267A1 (en) 2010-10-14
AU2010233409A1 (en) 2011-08-11
MX2011008614A (es) 2011-09-09
HK1161087A1 (en) 2012-08-24
CN102316876B (zh) 2013-07-17
JP2012517994A (ja) 2012-08-09
CL2011001775A1 (es) 2011-10-28
CA2750626C (en) 2013-10-01
EP2396006B1 (en) 2012-12-19
EP2396006A1 (en) 2011-12-21
US8551962B2 (en) 2013-10-08
ZA201105310B (en) 2012-09-26

Similar Documents

Publication Publication Date Title
ES2571041T3 (es) Composiciones antimicrobianas
AR065721A1 (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa. composiciones farmaceuticas.
IN2015DN01198A (es)
GT201200276A (es) Combinaciones de compuestos activos
CO6491104A2 (es) Combinaciones de inhibidor de patógenos de planta y métodos de uso
UY33937A (es) Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
GT200900201A (es) Formulaciones para el tratamiento del cáncer.
MX344021B (es) Composiciones fluidas que comprenden un agente de estructuración.
CL2008003406A1 (es) Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih.
CL2008003405A1 (es) Compuestos derivados de tienopiridina, inhibidores de la enzima integrasa del vih; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion por vih.
HN2008000188A (es) 7- aza- indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y su utilizacion
UY35103A (es) Compuestos de cefem 2-sustituidos
AR055838A1 (es) Formulaciones para microproyecciones recubiertas que tienen solubilidad controlada
HN2011003011A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
MX338413B (es) Formulaciones de pelicula para los dientes.
CR11285A (es) Composicion farmaceutica que contiene un antagonista del canal de calcio de tipo dihipropiridina y metodo para la prepacion de la misma
CO7250444A2 (es) Uso de seaprose para eliminar biopelículas bacterianas
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
CL2017001964A1 (es) Encapsulado de agentes activos de alta potencia.
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
CO6410307A2 (es) Formulación de doramectina en dosis elevada
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
PA8846401A1 (es) Sinergismo antibiótico
AR073057A1 (es) Combinaciones insecticidas de abamectina y ciflumetofeno y composiciones que las comprenden.
CO2018005491A2 (es) Formulación de combinación de dosis fija, eflornitina y sulindaco

Legal Events

Date Code Title Description
FC Application refused